Transcend Capital Advisors LLC Sells 101 Shares of Amgen Inc. (NASDAQ:AMGN)

Transcend Capital Advisors LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,501 shares of the medical research company’s stock after selling 101 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Amgen were worth $3,025,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Briaud Financial Planning Inc bought a new stake in shares of Amgen in the 3rd quarter valued at about $26,000. BOK Financial Private Wealth Inc. bought a new stake in Amgen during the 4th quarter worth approximately $29,000. OFI Invest Asset Management bought a new stake in Amgen during the 3rd quarter worth approximately $26,000. Planned Solutions Inc. bought a new stake in Amgen during the 4th quarter worth approximately $30,000. Finally, Providence Capital Advisors LLC bought a new stake in Amgen during the 3rd quarter worth approximately $30,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

AMGN traded up $0.60 during trading hours on Friday, reaching $269.98. The company’s stock had a trading volume of 2,436,959 shares, compared to its average volume of 2,035,139. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The company’s 50-day moving average is $275.10 and its 200-day moving average is $281.45. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The firm has a market cap of $144.81 billion, a PE ratio of 21.62, a price-to-earnings-growth ratio of 2.60 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same period last year, the firm posted $4.09 earnings per share. Amgen’s revenue was up 19.8% compared to the same quarter last year. On average, equities analysts forecast that Amgen Inc. will post 19.43 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Morgan Stanley lowered their target price on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $329.00 price target on shares of Amgen in a research report on Wednesday, April 3rd. UBS Group reduced their price target on Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, The Goldman Sachs Group upped their price target on Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and an average price target of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.